Skip to main content
SpringerLink
Log in

New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Research on improved treatment of HIV infection and pre-exposure prophylaxis continues. Poor adherence to treatment is the critical risk factor for virological failure and resistance development, and long-acting formulations of anti-HIV medications that need only infrequent dosing may facilitate long-term therapeutic responses. Importantly, long-acting formulations of therapeutic agents have been used to avoid missing doses or treatment fatigue to prescribed lifelong medications in a number of different medical fields, with demonstrable success. However, such formulations are associated with challenges, such as the prolongation of adverse events with the persistence of drug concentrations and concerns over the development of resistance as a result of selective pressure as drug concentrations decline. Furthermore, long-acting injectable formulations of antiretroviral (ARV) agents with infrequent dosing may be advantageous over daily oral drug intake to prevent transmission of HIV. However, the knowledge on protective drug concentrations and frequency of dosing is poor to date and implementation globally is challenging. Importantly, if nanoformulations of ARVs requiring lower drug doses become available globally, the potential for treatment cost reductions is high, as, especially in resource-limited settings, the active pharmaceutical ingredient accounts for the greater proportion of the total cost of the medicine. In conclusion, different long-acting ARVs are being studied in phase I/II for both the treatment and prevention of HIV infection, and research on administering these agents in combination has started.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012. British HIV Association; 2012 Apr. p. 1–139. Available from: http://www.bhiva.org/documents/Guidelines/Treatment/2012/120430TreatmentGuidelines.pdf.

  2. Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012;28:669–80.

    Google Scholar 

  3. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;24(366):1998–2007.

    Article  Google Scholar 

  4. Nieschlag E, Buchter D, Eckardstein von S, Abshagen K, Simoni M, Behre HM. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol. Blackwell Science Ltd. 1999;51:757–63.

    Google Scholar 

  5. Rossi GG, Frediani SS, Rossi RR, Rossi AA. Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations. BMC Psychiatry. 2012;12:122–2.

    Google Scholar 

  6. Dassah ET, Odoi AT, Owusu-Asubonteng G. Prevalence and factors predictive of long-acting reversible contraceptive use in a tertiary hospital in urban Ghana. Eur J Contracept Reprod Health Care. 2013;31(18):293–9.

    Article  Google Scholar 

  7. Prescott GM, Matthews CM. Long-acting reversible contraception: a review in special populations. Pharmacotherapy. 2013 [Epub ahead of print].

  8. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–34.

    Google Scholar 

  10. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.

    Google Scholar 

  11. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). In: 20th Conference on Retroviruses and Opportunitistic Infections (CROI). Atlanta, GA; 2013. Available from: http://www.retroconference.org/2013b/Abstracts/47951.htm.

  12. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–22.

    Google Scholar 

  13. Donnell D, Baeten JM, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, et al. Tenofovir disoproxil fumarate drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda. In: 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA.

  14. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Science Translational Medicine. 2012;11;4(151):ra125–5.

    Google Scholar 

  15. Wysham C, Grimm M, Chen S. Once weekly exenatide: efficacy, tolerability and place in therapy. Diabetes Obes Metab. 2013;15:871–81.

    Google Scholar 

  16. Owens DR, Matfin G, Monnier L. Basal insulin analogues in the management of diabetes mellitus: what progress have we made? Diabetes Metab Res Rev. 2013 [Epub ahead of print].

  17. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai M-Y, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;7(343):1666–72.

    Article  Google Scholar 

  18. Williams J, Sayles HR, Meza JL, Sayre P, Sandkovsky U, Gendelman HE, et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine (Lond). Future Med. 2013;8:1807–13.

    Google Scholar 

  19. Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, et al. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE studies. HIV Clin Trials. 2013;30(14):81–91.

    Article  Google Scholar 

  20. Baert L, van ‘t Klooster G, Dries W, ois MF, Wouters A, Basstanie E, et al. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm. 2009;72:502–8.

    Google Scholar 

  21. Jackson AGA, Else LJ, Mesquita PMM, Egan D, Back DJ, Karolia Z, et al. A pharmacokinetic evaluation of the exposure and distribution of rilpivirine long acting formulation for use as pre-exposure prophylaxis (PrEP), in plasma, female genital and male rectal compartments, following a single intramuscular dose at different doses in HIV negative volunteers (in press).

  22. Jackson AGA, Else LJ, Mesquita PMM, Egan D, Back DJ, Karolia Z, et al. A pharmacokinetic evaluation of rilpivirine long-acting formulation for use as pre-exposure prophylaxis (PrEP). In: Plasma, female genital and male rectal compartments, following single intramuscular doses in HIV negative volunteers.

  23. Verloes R, Klooster GV, Baert L, van Velsen F, Bouche M-P, Spittaels K, et al. TMC278 long acting—a parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers. In: XVIIth International AIDS Conference. Mexico City, Mexico; 2008. Available from: http://www.tibotec.com.

  24. Rimsky LL, Vingerhoets JJ, Van Eygen VV, Eron JJ, Clotet BB, Hoogstoel AA, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr. 2012;1(59):39–46.

    Article  Google Scholar 

  25. Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulié C, Fourati S, et al. Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses. J Antimicrob Chemother. 2013;14(68):1237–42.

    Article  Google Scholar 

  26. Underwood M, St Clar M, Johns B, Sato A, Fujiwara T, Spreen W. S/GSK1265744: a next generation integrase inhibitor (INI) with activity against raltegravir-resistant clinical isolates. AIDS 2010—XVIII International AIDS Conference; 2013.

  27. Min S, Dejesus EE, McCurdy L, Richmond G, Torres J, Ford S, et al. Pharmacokinetics (PK) and safety in healthy and HIV-infected subjects and short-term antiviral efficacy of S/GSK1265744, a next generation once daily hiv integrase inhibitor. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA; 2009. pp. 1–5.

  28. Yoshinaga T, Kobayashi M, Seki T, Kawasuji T, Taishi T, Sato A. Antiviral characteristics of S/GSK1265744, an HIV integrase inhibitor (INI) dosed by oral or long-acting parenteral injection. In: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA; 2012.

  29. Andrew C, Gettie A, Russell-Lodrigue K, Moss L, Mohri H, Spreen W, et al. Long-acting parenteral formulation of GSK1265744 protects macaques against repeated intrarectal challenges with SHIV. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA; 2013.

  30. Spreen W, Williams P, Margolis D, Ford S, Crauwels H, Lou Y, et al. First study of repeat dose co-administration of GSK1265744 and TMC278 long-acting parenteral nanosuspensions: pharmacokinetics, safety, and tolerability in healthy adults. In: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, Malaysia; 2013.

  31. Norris D, Morales J, Gathe J, Godofsky E, Garcia F, Hardwicke R, et al. Phase 2 efficacy and safety of the novel entry inhibitor, TNX-355, in combination with optimized background regimen (OBR). AIDS 2006—XVI International AIDS Conference. Toronto; 2006.

  32. Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human Immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 2009;22(53):450–7.

    Article  Google Scholar 

  33. Pace CSC, Fordyce MWM, Franco DD, Kao C-YC, Seaman MSM, Ho DDD. Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr. 2013;1(62):1–9.

    Article  Google Scholar 

  34. Gautam N, Roy U, Balkundi S, Puligujja P, Guo D, Smith N, et al. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob Agents Chemother. 2013;1(57):3110–20.

    Article  Google Scholar 

  35. Roy U, McMillan J, Alnouti Y, Gautum N, Smith N, Balkundi S, et al. Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1–infected human peripheral blood lymphocyte–reconstituted mice. J Infect Dis. 2012;15(206):1577–88.

    Article  Google Scholar 

  36. Dash PKP, Gendelman HEH, Roy UU, Balkundi SS, Alnouti YY, Mosley RLR, et al. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS. 2012;13(26):2135–44.

    Article  Google Scholar 

  37. McDonald TO, Giardiello M, Martin P, Siccardi M, Liptrott NJ, Smith D, et al. Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro–in vivo correlation. Adv Healthcare Mater. 2013 (in press).

  38. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clin Pharmacokinet. 1997;32:194–209.

    Google Scholar 

  39. Back DJ, Rogers SM. Review: first-pass metabolism by the gastrointestinal mucosa. Aliment Pharmacol Ther. 1987;1(1):339–57.

    CAS  PubMed  Google Scholar 

  40. Jackson A, Taylor S, Boffito M. Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors. AIDS Rev. 2004;6:208–17.

    PubMed  Google Scholar 

  41. Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman ANR, Walker DK. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol. 2008;31(65 Suppl 1):60–7.

    Article  Google Scholar 

  42. Cohen MSM, McCauley MM, Gamble TRT. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS. 2012;1(7):99–105.

    Article  Google Scholar 

Download references

Conflicts of interest

Dr. Marta Boffito was principal investigator on the SSAT040 study aimed at investigating the pharmacokinetics of rilpivirine long-acting, funded by the Bill and Melinda Gates Foundation. Dr. Marta Boffito and Prof. Andrew Owen have received funding from the Engineering and Physical Sciences Research Council towards Nanomedicine Interventions for HIV/AIDS.

Author information

Authors and Affiliations

  1. St. Stephen’s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK

    Marta Boffito & Akil Jackson

  2. University of Liverpool, Liverpool, UK

    Andrew Owen

  3. Bill and Melinda Gates Foundation, Seattle, WA, USA

    Stephen Becker

Authors
  1. Marta Boffito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akil Jackson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew Owen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marta Boffito.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boffito, M., Jackson, A., Owen, A. et al. New Approaches to Antiretroviral Drug Delivery: Challenges and Opportunities Associated with the Use of Long-Acting Injectable Agents. Drugs 74, 7–13 (2014). https://doi.org/10.1007/s40265-013-0163-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-013-0163-7

Keywords

Search

Navigation